Serving 50,000+ members
Create New Account Login
 

Chinese Diabetes Market to Reach USD 2.8 Billion by 2015

A new report expects the Chinese diabetes market to grow exponentially in the coming years.

Market Press Release – April 24, 2012 9:24 am
Contact Information
Krishna sharma
sec-10, Noida
Noida
UP - 201301
India
91-120-4256531
press@imarcgroup.com
 
A new report from IMARC Group entitled “China Diabetes Market Outlook (2010-2015)” expects the Chinese diabetes market to grow at a CAGR of 28% during 2011-2015 reaching revenues worth USD 2.8 Billion. The report gives a comprehensive insight into the Chinese diabetes market and serves as an excellent tool to understand not only the market trends, structure, drivers and restraints but also the outlook of the market till 2015. This report aims to serve as a statistical as well as an analytical guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into Chinese diabetes market in some form or the other.

Report Highlights

• In 2009, the market for Non-Insulin Anti-diabetics was worth US$ 357 Million. Four of the top five players were foreign multinationals, with Bayer being the leader with a 28% market share.
• Alpha Glycosidase Inhibitors represented the biggest non Insulin Anti-diabetes class with a share of 35% in 2009.
• Although DPP-IV Inhibitors have been available in China only since march 2010. We expect this class to show a strong uptake in the next five years and reach revenues worth US$ 172 Million.
• China’s Insulin market witnessed a CAGR growth of 31% between 2005-2009 and was worth US$ 285 Million in 2009.
• The Chinese Insulin market is strongly oligopolistic with top three players (all of them being multinationals) accounting for 92% of the total sales in 2009. In fact, one player (Novo Nordisk) accounted 71% of the total sales.

Forecasts: The report provides forecasts on:
• Number of diabetes patients
• Diagnosis and treatment rates in China
• Diabetes market
• Non-Insulin Anti-diabetics market
• Alpha-Glycosidase Inhibitors
• Glinides
• Glitazones
• Sulphonylureas
• DPP-IV Inhibhitors
• Biguanides
• GLP-1 Agonists
• All other Non-Insulin Anti-diabetic classes
• Insulin market

Competitive Landscape: This section covers:
• 2005-2009 sales and market shares of top players in the diabetes market
• 2005-2009 sales and market shares of top players in the Non-Insulin Anti-diabetics market
• 2005-2009 sales and market shares of top players in various Non-Insulin Drug Classes
• 2005-2009 sales of top drugs comprising the portfolio of key players in various Non-Insulin Drug Classes
• 2005-2009 sales and market shares of top players in the Insulin market
• 2005-2009 sales of top drugs comprising the portfolio of Key players in the Insulin market.

Key Questions Answered in this report
• What is the total size of the diabetes population in China and what are its characteristics?
• What are the diagnosis and drug treatment rates for diabetes in China?
• What are the key factors driving the growth of diabetes medication in China?
• What is the Size and Breakup of the total diabetes market in China?
• What is the Size and Breakup of the total Non-Insulin Anti-diabetics market in China?
• What is the Size and Breakup of the total Insulin market in China?
• Who are the key players in the Chinese diabetes market and how have they performed?
• What is the outlook of the Chinese diabetes market in the next five years?
• Which new products are expected to be launched in the next five years?
• Which therapy classes will show the highest growth in the next five years?
• What are the road blocks in the Chinese diabetes market?


TABLE OF CONTENTS

1.EXECUTIVE SUMMARY
2.DIABETES DISEASE OVERVIEW
2.1 WHAT IS DIABETES?
2.2 DIABETES DIAGNOSIS AND TREATMENT
2.2.1 Diagnosis
2.2.2 Treatment
2.3 DIABETES COMPLICATIONS
3.THE CHINESE DIABETES MARKET: WHY IS IT SO LUCRATIVE?
3.1 CHINA HAS ONE OF THE LARGEST DIABETES PATIENT POOLS IN THE WORLD.
3.2 CHINA REPRESENTS ONE OF THE FASTEST GROWING MARKETS GLOBALLY
3.3 INCREASING AFFORDABILITY OF HEALTHCARE
3.4 MORE THAN A BILLION DOLLARS WORTH OF MARKET REMAINS UNTAPPED
3.5 A BETTER IPR REGIME IS DRIVING THE LAUNCH NEW AND INNOVATIVE DRUGS
4.DRIVERS OF DIABETES IN CHINA
4.1 AGEING POPULATION
4.2 INCREASING OBESITY LEVELS
4.3 URBANIZATION
5.THE CHINESE DIABETES EPIDEMIOLOGY
5.1 TOTAL PREVALENCE
5.1.1 Urban and Rural Prevalence
5.1.2 Prevalence of Diabetes by Sex
5.1.3 Prevalence of Diabetes by Age Group
5.2 DIAGNOSIS AND TREATMENT RATES IN CHINA
6.THE CHINESE DIABETES MARKET
6.1 MARKET TREND (2005-2009)
6.2 MARKET SEGMENTATION (2005-2009)
6.3 MARKET FORECASTS (2010-2015)
7.THE CHINESE NON-INSULIN ANTI-DIABETICS MARKET
7.1 MARKET TREND (2005-2009)
7.2 COMPETITIVE LANDSCAPE (2005-2009)
7.3 MARKET FORECASTS (2010-2015)
7.4 MARKET SEGMENTATION (2005-2015)
7.4.1 Alpha-Glycosidase Inhibitors
7.4.1.1 Market Trend (2005-2009)
7.4.1.2 Competitive Landscape
7.4.1.3 Market Forecasts (2010-2015)
7.4.2 Glinides
7.4.2.1 Market Trend (2005-2009)
7.4.2.2 Competitive Landscape
7.4.2.3 Market Forecasts (2010-2015)
7.4.3 Glitazones
7.4.3.1 Market Trend (2005-2009)
7.4.3.2 Competitive Landscape
7.4.3.3 Market Forecasts (2010-2015)
7.4.4 Sulphonylurea
7.4.4.1 Market Trend (2005-2009)
7.4.4.2 Competitive Landscape
7.4.4.3 Market Forecasts (2010-2015)
7.4.5 Biguanides
7.4.5.1 Market Trend (2005-2009)
7.4.5.2 Competitive Landscape
7.4.5.3 Market Forecasts (2010-2015)
7.4.6 Dpp-IV Inhibitors
7.4.6.1 Competitive Landscape
7.4.6.2 Market Forecasts (2010-2015)
7.4.7 Glp-1 Agonists
7.4.7.1 Competitive Landscape
7.4.7.2 Market Forecasts (2010-2015)
7.4.8 All other Classes
7.4.8.1 Market Trend (2005-2009)
7.4.8.2 Competitive Landscape
7.4.8.3 Market Forecasts (2010-2015)
8.THE CHINESE INSULIN MARKET
8.1 MARKET TREND (2005-2009)
8.2 MARKET SEGMENTATION BY MOLECULE (2005-2009)
8.3 MARKET SEGMENTATION BY MODE OF ACTION
8.4 COMPETITIVE LANDSCAPE
8.4.1 Share of key Players
8.4.2 Insulin Portfolio of Key Players
8.5 MARKET FORECASTS (2005-2010)
9.ROAD BLOCKS
9.1 MILLIONS DON’T EVEN KNOW IF THEY HAVE DIABETES
9.2 DESPITE THE LARGE POPULATION BASE, AVERAGE SPENDING ON DIABETES REMAINS FAIRLY LOW
9.3 REGULATORY & BUREAUCRATIC HURDLES
9.4 LARGE FINANCIAL DISPARITY


To buy the complete report or to get a free sample, please contact:

IMARC Group Asia
Email: apac@imarcgroup.com
Phone: +91-120-425-6531

IMARC Group North America
Email: america@imarcgroup.com
Phone: +1-631-791-1145

IMARC Group Europe, Middle East & Africa
Email:ema@imarcgroup.com
Phone: +44-702-409-7331

To know more please visit: http://www.imarcgroup.com/china-diabetes-market-report-and-outlook-2010-2015/


For more information, visit: http://www.imarcgroup.com

Related Tags: Chinese diabetes market, Chinese insulin market, Non insulin diabetes market, DPP-IV Inhibitor

Disclaimer

If you have any questions regarding information in this press release, please contact the person listed in the Contact / Company information box of this page. Please do not attempt to contact Market Press Release. We will be unable to assist you with any information regarding this release. Market Press Release disclaims any content contained in this press release.
Related Press Releases In This Category
  Blue Sky Peptide Encourage Customers to Buy Ipamorelin from Reputable Sources
  Detect Caffeine with Elisa Kits-See the Facts
  Geniebio Corp. Manufacturing Premium Quality Medical Centrifuges
  Creative Biolabs Launches Monoclonal Canine Antibody Production Service
  Animal Antimicrobials and Antibiotics Market worth $4,143.8 Million by 2018